Marengo to Present a Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Clinical Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoint Blockade